EP4599253A1 - Utilisation de profils d'isoformes d'albumine pour caractérisation d'étiologie et de gravité des lésions hépatiques - Google Patents

Utilisation de profils d'isoformes d'albumine pour caractérisation d'étiologie et de gravité des lésions hépatiques

Info

Publication number
EP4599253A1
EP4599253A1 EP23785803.0A EP23785803A EP4599253A1 EP 4599253 A1 EP4599253 A1 EP 4599253A1 EP 23785803 A EP23785803 A EP 23785803A EP 4599253 A1 EP4599253 A1 EP 4599253A1
Authority
EP
European Patent Office
Prior art keywords
liver
albumin
isoforms
alb
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23785803.0A
Other languages
German (de)
English (en)
Inventor
Souleiman EL BALKHI
François-Ludovic SAUVAGE
Pierre Marquet
Franck SAINT-MARCOUX
Mohamed-Ali RAHALI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Limoges
Centre Hospitalier Universitaire de Limoges
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Limoges
Centre Hospitalier Universitaire de Limoges
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Limoges, Centre Hospitalier Universitaire de Limoges filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of EP4599253A1 publication Critical patent/EP4599253A1/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Definitions

  • the present invention is in the field of medicine, in particular hepatology.
  • HSA human serum albumin
  • the term “subject” as used herein refers to any mammal organism.
  • the term subject includes, but is not limited to, humans, nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like.
  • the term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.
  • the term “etiology” refers to the causes or origins, of diseases or abnormal physiological conditions.
  • Alb+SO3H or “Alb-CysO3” refers to an albumin isoform characterized by a trioxidation.
  • Alb+Cys-DHA refers an albumin isoform characterized by a cysteinylation of the Cys34 and a transformation of a free cysteine to a dehydroalanine.
  • Alb+Glyc refers to an albumin isoform characterized by a glycation/
  • Alb+SO2H+Glyc refers to an albumin isoform characterized by a dioxidation and a glycation.
  • Alb+SO3H+Glyc refers to an albumin isoform characterized by a trioxidation and a glycation.
  • Alb+Cys+Glyc-DHA refer to an albumin isoform characterized by a cysteinylation of the Cys34, a glycation and a transformation of a free cysteine to a dehydroalanine.
  • Alb-SGGS refers to an albumin isoform characterized by a glutathionylation.
  • Alb+2Glyc refers to an albumin isoform characterized by two glycations.
  • Alb+SO3H+2Glyc refers to an albumin isoform characterized by a trioxidation and two glycations.
  • Alb+Cys+2Glyc refers to an albumin isoform characterized by a cysteinylation of the Cys34 and two glycations.
  • the term "profile" means a pattern and relates to the magnitude and direction of change of a number of features.
  • the profile may be interpreted stringently, i.e., where the variation in the magnitude and/or number of features within the profile displaying the characteristic is substantially similar to a reference profile or it may be interpreted less stringently, for example, by requiring a trend rather than an absolute match of all or a subset of feature characteristics.
  • MS mass spectrometry
  • MS refers to an analytical technique to identify compounds by their mass.
  • MS refers to methods of filtering, detecting, and measuring ions based on their m/z.
  • MS technology generally includes (1) ionizing the compounds to form charged species (e.g., ions); and (2) detecting the molecular weight of the ions and calculating their m/z.
  • the compounds may be ionized and detected by any suitable means.
  • a “mass spectrometer” generally includes an ionizer and an ion detector.
  • one or more molecules of interest are ionized, and the ions are subsequently introduced into a mass spectrometric instrument where, due to a combination of magnetic and electric fields, the ions follow a path in space that is dependent upon mass (“m”) and charge (“z”).
  • m mass
  • z charge
  • U.S. Pat. No. 6,204,500 entitled “Mass Spectrometry From Surfaces;”
  • U.S. Pat. No. 6,107,623 entitled “Methods and Apparatus for Tandem Mass Spectrometry;”
  • U.S. Pat. No. 6,268,144 entitled “DNA Diagnostics Based On Mass Spectrometry;” U.S. Pat. No.
  • blood sample means a whole blood, serum, or plasma sample obtained from the patient or the animal.
  • the first object of the present invention relates to a method of determining the etiology and severity of a liver injury in a subject comprising determining the profile of albumin isoforms in a blood sample obtained from the subject wherein the profile indicates the etiology and severity of the liver injury.
  • the method of the present invention comprises the step of detecting a plurality of albumin isoforms. Even, more particularly, the method of the present invention comprises the step of detecting a plurality of albumin isoforms selected from Table 4. In some embodiments, the method of the present invention comprises the step of detecting a plurality of isoforms selected from the group consisting of Alb+SO2H, HSA-CysO3, Alb+Cys-DHA, Alb+Cys, Alb+Cys+SNO, Alb+SO2H+Glyc, Alb+SO3H+Glyc, HAS-SGGS, Alb+2Glyc, Alb+SO3H+2Glyc, and Alb+Cys+2Glyc.
  • the method of the present invention comprises the steps of i) determining the profile of albumin isoforms in the blood sample obtained from the patient, and ii) comparing the profile to one or more reference profiles associated with various liver injuries.
  • the method of the present invention is particularly suitable for detecting any kind of liver injury. In some embodiments, the method of the present invention is particularly suitable for detecting chemical liver injuries. In some embodiments, the method of the present invention is particularly suitable for detecting physical liver injuries. In some embodiments, the method of the present invention is particularly suitable for detecting ischemic liver injuries.
  • the method of the present invention is particularly suitable for the early detection of a liver injury, i.e. the detection of a liver injury before the observation of a symptom.
  • the method of the present invention is particularly suitable for the early detection of early graft dysfunction or non-function in liver transplanted patients.
  • the method of the present invention is particularly suitable for detecting a chemical liver injury induced by a toxicant selected from the group consisting of alcohol, 2,2 Z ,4,4 Z ,5,5 Z -hexachlorobiphenyl (PCB-153), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 2-bromoethylamine (BEA), 3-methylcholanthrene, 4-aminophenol (PAP), acetaminophen (APAP), adriamycin, allyl alcohol, amiodarone, amphotericin B, Aroclor 1254, Aroclor 1260, arsenic, aspirin, astemizole, benzene, cadmium, carbamezipine, carbon tetrachloride (CC14), ciprofibrate (cipro), clofibrate, cobalt chloride, corvastatin, cyclosporin A, diethylnitros
  • the method of the present invention is particularly suitable for detecting a liver injury selected from the group consisting of liver abscess, liver cancer, either primary or metastatic, cirrhosis, such as cirrhosis caused by the alcohol consumption or primary biliary cirrhosis, amebic liver abscess, autoimmune hepatitis, biliary atresia, coccidioidomycosis disseminated, portal hypertension hepatic infections (such as hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, or hepatitis E virus), hemochromatosis, hepatocellular carcinoma, pyogenic liver abscess, Reye's syndrome, sclerosing cholangitis, Wilson's disease, drug induced hepatotoxicity, or fulminant or acute liver failure.
  • cirrhosis such as cirrhosis caused by the alcohol consumption or primary biliary
  • the method of the present invention is particularly suitable for detecting a non-alcoholic fatty liver disease, and in particular for detecting NASH.
  • the method of the present invention is particularly suitable for detecting liver fibrosis.
  • the method of the present invention is particularly suitable for detecting cirrhosis.
  • the method of diagnosing described herein is applied to a subject who presents symptoms of liver injury without having undergone the routine screening to rule out all possible causes for liver injury.
  • the methods described herein can be part of the routine set of tests performed on a subject who presents symptoms of liver injury such as jaundice, abdominal pain and swelling, swelling in the legs and ankles, itchy skin, dark urine color, pale stool color, bloody color stool, tar-colored stool, chronic fatigue, nausea or vomiting, loss of appetite, tendency to bruise easily. . .
  • the method of the present invention can be carried out in addition of other diagnostic tools that include ultrasound evaluation (e.g.
  • elastography biopsy and/or quantification of at least one further biomarkers such as levels of blood AST, ALT, ALP, TTT, ZTT, total bilirubin, total protein, albumin, lactate dehydrogenase, choline esterase and the like.
  • a further object to the present invention relates to a method of predicting the worsening of a liver injury comprising the steps of determining the evolution of the profile of albumin isoforms in the blood sample obtained from the patient wherein said evolution predicts the worsening of the liver injury.
  • a further object of the present invention relates to a method of predicting an early allograft liver dysfunction or liver non-function in a liver-transplanted patient comprising the steps of determining the evolution of the profile of albumin isoforms in the blood sample obtained from the patient wherein said evolution predicts the early allograft dysfunction or non-function.
  • the isoforms are detected by mass spectrometry.
  • the isoform is identified visually by its mass shift with respect to native albumin and by taking the maximum intensity in a mass interval of 10 Da around the observed peak of each isoform.
  • Table 4 indicates the different mass shifts that are associated with Alb+SO2H, HSA-CysO3, Alb+Cys-DHA, Alb+Cys, Alb+Cys+SNO, Alb+SO2H+Glyc, Alb+SO3H+Glyc, HSA-SGGS, Alb+2Glyc, Alb+SO3H+2Glyc, and Alb+Cys+2Glyc.
  • Mass spectrometry is performed using a mass spectrometer, which includes an ion source for ionizing the fractionated sample and creating charged molecules for further analysis.
  • Ionization sources used in various MS techniques include, but are not limited to, electron ionization, chemical ionization, electrospray ionization (ESI), photon ionization, atmospheric pressure chemical ionization (APCI), photoionization, atmospheric pressure photoionization (APPI), fast atom bombardment (FAB)/liquid secondary ionization (LSIMS), matrix assisted laser desorption ionization (MALDI), field ionization, field desorption, thermospray/plasmaspray ionization, surface enhanced laser desorption ionization (SELDI), inductively coupled plasma (ICP) and particle beam ionization.
  • ESI electron ionization
  • APCI atmospheric pressure chemical ionization
  • APPI atmospheric pressure photoionization
  • FAB fast atom bombardment
  • LIMS
  • the choice of ionization method may be determined based on the analyte to be measured, type of sample, the type of detector, the choice of positive versus negative mode, etc.
  • the positively charged ions thereby created may be analyzed to determine m/z.
  • Suitable analyzers for determining m/z include quadrupole analyzers, ion trap analyzers, and time-of- flight analyzers.
  • the ions may be detected using one of several detection modes. For example, only selected ions may be detected using a selective ion monitoring mode (SIM), or alternatively, multiple ions may be detected using a scanning mode, e.g., multiple reaction monitoring (MRM) or selected reaction monitoring (SRM).
  • SIM selective ion monitoring mode
  • MRM multiple reaction monitoring
  • SRM selected reaction monitoring
  • a precursor ion also called a parent ion
  • the precursor ion subsequently fragmented to yield one or more fragment ions (also called daughter ions or product ions) that are then analyzed in a second MS procedure.
  • fragment ions also called daughter ions or product ions
  • the MS/MS technique may provide an extremely powerful analytical tool.
  • the combination of filtration/fragmentation may be used to eliminate interfering substances, and may be particularly useful in complex samples, such as biological samples.
  • recent advances in technology such as matrix-assisted laser desorption ionization coupled with time- of-flight analyzers (“MALDI-TOF”) permit the analysis of analytes at femtomole levels in very short ion pulses.
  • MALDI-TOF time- of-flight analyzers
  • MS/MS mass spectrometry steps
  • MS/MS/TOF MS/MS/TOF
  • MALDI/MS/MS/TOF MALDI/MS/MS/TOF
  • SELDI/MS/MS/TOF mass spectrometry SELDI/MS/MS/TOF mass spectrometry.
  • the blood samples are processed to obtain preparations that are suitable for analysis by mass spectrometry.
  • Such purification will usually include chromatography, such as liquid chromatography or capillary electrophoresis, and may also often involve an additional purification procedure that is performed prior to chromatography.
  • chromatography such as liquid chromatography or capillary electrophoresis
  • Various procedures may be used for this purpose depending on the type of sample or the type of chromatography. Examples include filtration, centrifugation, combinations thereof and the like.
  • the pH of the serum sample may then be adjusted.
  • the sample may be purified with a filtration.
  • the filtrate from this filtration can then be purified by liquid chromatography and subsequently subjected to mass spectrometry analysis.
  • HPLC high performance liquid chromatography
  • One or more steps of the methods may be performed using automated machines.
  • one or more purification steps are performed on-line, and more preferably all of the LC purification and mass spectrometry steps may be performed in an on-line fashion.
  • the method of the present invention can also be useful for monitoring the subject.
  • the method of the present invention is also particularly suitable for determining whether a subject suffering from a liver injury achieves a response to a therapy.
  • the method is thus particularly suitable for discriminating responder from non-responder.
  • responder in the context of the present disclosure refers to a subject that will achieve a response, i.e. a subject who is under remission and more particularly a subject who does not suffer from liver injury.
  • a “non-responder” subject includes subjects for whom the disease does not show reduction or improvement after the treatment (e.g. the liver injury remains stable or decreases). For instance, the nature and the abundance of the different isoforms can indeed be monitored during the treatment of the subject and thus can indicate whether the subject achieves a response to the therapy.
  • FIG. 1 Evolution of albumin isoforms in the different groups of rats exposed to CCI4 for different time durations. Native albumin is expressed as percent of the sum of all detected isoforms. Other isoforms are expressed in relative abundances of the native albumin.
  • Figure 8 A. PCA-DA plot of the 4 groups of patients. Each dot represents the whole information of the albumin profile for one patient. Square dots are control patients, circle dots represent stage A, circles dots stage B, triangle dots represent stage C cirrhosis patients. B. PCA-DA plot of 3 groups of patients: stage A, B and C.
  • EAD+ are patients in whom early allograft dysfunction has been diagnosed based on the LGrAFTIO or the EAD scores.
  • EAD- are patients with no graft dysfunction detected.
  • Each dot represents the whole information of the albumin profile for one patient at VI (24 hours before transplantation) subtracted from the whole information of the albumin profile at V6 (7 days after transplantation).
  • FIG. 10 PLS-DA plot of 2 groups of patients.
  • EAD+ are patients in whom early allograft dysfunction has been diagnosed based on the LGrAFTIO or the EAD scores.
  • EAD- are patients with no graft dysfunction detected.
  • Each dot represents the whole information of the albumin profile for one patient at VI (24 hours before transplantation) subtracted from the whole information of the albumin profile at V3 (72 hours after transplantation).
  • hepatotoxicity was induced by oral administration (gavage) of 2 mL of a 50% EtOH solution prepared in physiological saline (0.9% NaCl) to evaluate the timedependent changes in biochemical markers and histological liver injuries.
  • 6 to 9 rats were followed for 1, 3, 7, 10, or 14 days, respectively. All rats received the daily dose of EtOH.
  • the animals were sacrificed 24 hours after their last intake of EtOH. “Control” rats were followed throughout the duration of the protocol, ie 14 days, and received by gavage only physiological serum (0.9% NaCl).
  • APAP paracetamol
  • Plasma samples were collected in Vacutainer® lithium heparin tube for trace elements (Beckton Dickinson, France) and then centrifuged at 3000 rpm for 10 minutes. The plasma samples were then stored at -80 ° C until analysis. Rat livers were quickly removed and fixed in formalin for histological analysis.
  • livers were cut into sections of 1 to 1.5 cm perpendicular to the major axis to allow homogeneous fixation in a 4% formalin solution for a maximum of 7 days. Samples were stained for light microscopy with hematoxylin and eosin staining and Masson's trichrome stain. The pathologist performed histological analysis blindly, with no knowledge of the different experimental groups.
  • a volume of 20 pL of plasma was diluted with 980 pL of an aqueous 20mM ammonium formate solution with 0.1 % formic acid, and then vortex-mixed. The mixture was centrifuged at 10°C and 14 000 g, and 300 pl of the supernatant was then filtered on a 0.22 pm cellulose acetate filter before injection.
  • Chromatographic separation was performed using a Nexera LC40 system (Shimadzu, noisysiel, France) equipped with a thermostated column compartment and a thermostated autosampler with a six-port switching valve. Samples were analyzed without chromatographic separation under isocratic conditions using a 2mM aqueous ammonium formate solution containing 0.1% formic acid as mobile phase A and a mixture of acetonitrile/mobile phase A (90: 10, by volume) as mobile phase B, programmed as follows: 0-3 min, 50% B.
  • Mass spectrometric detection was performed using a Q-TOF mass spectrometer (TripleTOF® 5600+, Sciex, Concord, Canada) equipped with a DuoSpray ion source and operated in the positive ionization mode.
  • a beta-galactosidase solution was used for internal calibration.
  • the source conditions were as follows: temperature, 200 °C; declustering potential (DP), 250 eV; curtain gas (CUR), 40 units; ion source gas (GS1, GS2), respectively 70 and 10 units; and ionspray voltage floating, 5.5 kV. All MS parameters were controlled by Analyst® TF 1.7 (Sciex). Data were processed with PeakView® 2.2 software (Sciex). m/z ratios were scanned using a TOF MS scan from m/z 900 and 1800 with an accumulation time of 500 ms.
  • the LC-MS data were processed using PeakView® 2.2 software and its Bio Tool Kit 2.2.0 feature (Sciex).
  • the input MS spectra selected from 1300 to 1600 was then deconvolved using a low resolution (5000) from m/z 1000 to 200000.
  • Deconvolution spectra (or profiles) are expressed as intensity versus mass in Da. Estimation of the relative abundance of isoforms.
  • each isoform was determined after calculating the ratio between each centroided peak and the total area represented by the sum of the centroid peaks between 65500 and 67000 for rat serum albumin or 66000 to 67500 for human serum albumin.
  • Each isoform was identified visually by its mass shift with respect to native albumin and by taking the maximum intensity in a mass interval of 10 Da around the observed peak of each isoform.
  • the relative proportion of the intensity of each isoform was calculated by dividing the intensity or area obtained from its deconvoluted spectrum by the summed intensity of all isoforms (between 65500 and 67000) and multiplying it by 100. Data were gathered in an Excel file then analyzed using GraphPad® for the potential isoforms.
  • Relative abundance was calculated as the ratio between the maximum intensity of each identified isoform compared that of the native isoform.
  • the cohort was composed of cirrhotic patients and of patients with no liver dysfunction as controls. Patients were considered as free from liver dysfunction on the basis of their clinical diagnosis and their liver function biochemical tests, namely, aspartate transaminase, alanine transaminase, alkaline phosphatase, y-glutamyltransferase, free and total bilirubin, and albumin levels.
  • Cirrhotic patients were included based on an hepatologist’s diagnosis, their liver function biochemical tests and their Child-Pugh scores.
  • Patient plasma samples were prepared as previously described and albumin isoforms were analyzed and identified as previously described for rat plasma samples.
  • Albumin isoforms were characterized for 38 cirrhotic patients and 52 control patients (with no liver injuries). Among the cirrhotic patients, 18 were diagnosed with alcoholic liver disease (ALD), 5 had a nonalcoholic steatosis (NASH) and 16 were diagnosed with a mixed origin of ALD and NASH. The isoforms detected are depicted in Figure 6 where we can observe a decrease of native albumin in all cirrhotic patients. This decrease was the most important in NASH patients. Generally, the increase of the different isoforms was not homogenous among the three groups of patients (Table 5). HSA-DA+Cys and HSA+SO2H were only significantly increased in patients with cirrhosis of mixed origin.
  • HSA+SGGS and HSA+2Glyc were increased only in NASH patients.
  • PCA- DA showed a clear clustering between the 4 groups, namely, control patients, NASH patients, ALD patients and the mixed-cirrhosis patients (Figure 7).
  • stage A (calculated on the basis of Child- Pugh score)
  • stage B (calculated on the basis of Child- Pugh score)
  • stage C (calculated on the basis of Child- Pugh score)
  • PCA-DA showed a clear clustering of the different stages of cirrhosis and the control patients (Figure 8).
  • Albumin isoforms were characterized in 38 liver-transplanted patients at different times: VI (24h before the transplantation), V2 (during the transplantation), V3 (24h after the transplantation), V4 (48h after the transplantation), V5 (72h after the transplantation), V6 (7 days after the transplantation).
  • VI 24h before the transplantation
  • V2 disuring the transplantation
  • V3 24h after the transplantation
  • V4 48h after the transplantation
  • V5 72h after the transplantation
  • V6 7 days after the transplantation.
  • albumin isoforms profiles when taken individually at each time, were not able to discriminate patients with an early allograft dysfunction, the subtraction of the profiles obtained at V6 -VI or V6-V3 allowed a clear clustering of these patients as shown in figure 9 and figure 10 respectively. Discussion:
  • ASK1 along with activated mixed-lineage kinase 3 (MLK3) then activated c-jun N-terminal kinase (JNK) to its phosphorylated form through MKK4 phosphorylation.
  • JNK c-jun N-terminal kinase
  • Phosphorylated JNK translocates to the mitochondria and binds to Sab on the outer mitochondrial membrane, which, through a Src-mediated pathway, further inhibits mitochondrial electron transport. This amplifies mitochondrial oxidant stress, which is further exacerbated by translocation of Bax and glycogen synthase kinase-3p (GSK-3P) from the cytosol to the mitochondria.
  • GSK-3P glycogen synthase kinase-3p
  • necrosis was mainly observed in rats given 4 g/kg APAP, and inflammation was noted for all doses.
  • Native albumin in this model did not decrease 24 hours post APAP and was even barely detectable at 72h , which is consistent with the mechanism of APAP toxicity described here. The sharp decrease of native albumin was associated with an increase in other isoforms. Among them, Alb+SGGS was specific to this APAP model. As we did not observe any normalization of native albumin, we can assume that the regeneration phase was not reached in our experimental conditions.
  • albumin can undergo several chemical modifications on several sites of its amino acids chain, including: cysteinylation, homocysteinylation, glutathionylation, glycation, nitrosylation, nitration, oxidation and carbonylation.
  • cysteinylation homocysteinylation
  • glutathionylation glutathionylation
  • glycation nitrosylation
  • nitration oxidation and carbonylation
  • the deconvoluted MS spectrum is capable of identifying unknown modifications because the addition or subtraction of a structural modification result in a characteristic mass shift, equal to the mass of the specific modification (for example, a mass difference of 163 Da for a glycation).
  • the 17 isoforms identified had to be “visually detectable” to be included, increasing the risk of leaving behind minor isoforms with low signals. Therefore, to investigate the differences in isoform distribution among the 3 animal models, we decided to integrate the whole information from each spectrum in PCA-DA. The profiles obtained with the 3 models were nicely separated ( Figure 5), suggesting that the Alb profile of each model depends on the different chemical environment and mechanisms of intracellular reactions generated by each substance, as previously explained.
  • albumin isoform profiles represent rich data that could help diagnosing liver diseases, staging them and sorting out their origin.
  • D2g-Dl is the group of rats that were sacrificed 24h after receiving a dose of 2 g/kg of APAP.
  • D2g-D3 is the group of rats that were sacrificed 72h after receiving a dose of a dose of 2g/kg.
  • D3g-Dl is the group of rats that were sacrificed 24h after receiving 3g/kg of APAP.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Les inventeurs ont supposé que chaque type de lésion hépatique peut être révélé par un profil spécifique de modifications post-traductionnelles de la sérumalbumine humaine (HSA). Par conséquent, l'objectif des inventeurs a été d'étudier le motif d'isoformes d'albumine chez des rats intoxiqués avec de l'acétaminophène (APAP), de l'éthanol et du CCI4. Le second objectif était d'explorer le potentiel de ces isoformes en tant que biomarqueurs de lésions spécifiques du foie. Les résultats démontrent que les modifications post-traductionnelles de l'albumine (Alb-PTM) interviennent très tôt au cours des lésions hépatiques induites par des substances hépatotoxiques. Dans trois modèles animaux, l'albumine native a commencé à diminuer au profit d'autres isoformes 24 heures après l'administration d'APAP, d'éthanol ou de CCI4. Il est intéressant de noter que la nature et l'intensité des isoformes sont différentes en fonction de la substance hépatotoxique. Dans une cohorte de patients cirrhotiques, les inventeurs ont pu identifier jusqu'à 14 isoformes d'albumine, tous également présents chez les patients témoins. Cependant, les inventeurs ont observé que l'augmentation de l'isoforme HSA-DA était spécifique aux patients atteints d'une cirrhose due à l'abus d'alcool, que les isoformes HSA+SGGS et HSA+2Glyc étaient augmentés spécifiquement chez les patients avec stéatohépatite non alcoolique, et que les isoformes HSA-DA+Cys et HSA+SO2H n'étaient augmentés que chez les patients atteints de la forme mixte. En outre, aucun isoforme spécifique n'a été observé, permettant de discriminer clairement les différents stades de la maladie hépatique, mais l'analyse en composantes principales de l'ensemble des données SM a permis de séparer parfaitement les patients atteints de cirrhose avec différents scores de Child-Pugh et les patients témoins. La présente invention concerne donc l'utilisation des profils d'isoformes d'albumine pour la caractérisation de l'étiologie et de la gravité des lésions hépatiques.
EP23785803.0A 2022-10-07 2023-10-06 Utilisation de profils d'isoformes d'albumine pour caractérisation d'étiologie et de gravité des lésions hépatiques Pending EP4599253A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22306513 2022-10-07
PCT/EP2023/077721 WO2024074685A1 (fr) 2022-10-07 2023-10-06 Utilisation de profils d'isoformes d'albumine pour caractérisation d'étiologie et de gravité des lésions hépatiques

Publications (1)

Publication Number Publication Date
EP4599253A1 true EP4599253A1 (fr) 2025-08-13

Family

ID=83903298

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23785803.0A Pending EP4599253A1 (fr) 2022-10-07 2023-10-06 Utilisation de profils d'isoformes d'albumine pour caractérisation d'étiologie et de gravité des lésions hépatiques

Country Status (2)

Country Link
EP (1) EP4599253A1 (fr)
WO (1) WO2024074685A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
CA2512290C (fr) 1993-05-28 2010-02-02 Baylor College Of Medicine Methode et appareil pour la desorption et l'ionisation d'analytes
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
WO1999038194A1 (fr) 1998-01-23 1999-07-29 Analytica Of Branford, Inc. Spectrometrie de masse depuis des surfaces
US8126690B2 (en) 2007-05-18 2012-02-28 The Regents Of The University Of Michigan Algorithms to predict clinical response, adherence, and shunting with thiopurines
US20100273661A1 (en) 2007-06-15 2010-10-28 Smithkline Beecham Corporation Methods and Kits for Predicting Treatment Response in Type II Diabetes Mellitus Patients
US20150377883A1 (en) * 2014-05-15 2015-12-31 The Regents Of The University Of Michigan Biomarkers of acute liver injury
EP3884280B1 (fr) * 2018-11-20 2024-01-17 Institut National de la Santé et de la Recherche Médicale (INSERM) Procédés et kits permettant de diagnostiquer un dysfonctionnement du foie chez un sujet

Also Published As

Publication number Publication date
WO2024074685A1 (fr) 2024-04-11

Similar Documents

Publication Publication Date Title
Niu et al. Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease
Mishur et al. Applications of mass spectrometry to metabolomics and metabonomics: Detection of biomarkers of aging and of age‐related diseases
US20210116467A1 (en) Diabetes-related biomarkers and treatment of diabetes-related conditions
Xia et al. Targeted metabolomic analysis of 33 amino acids and biogenic amines in human urine by ion‐pairing HPLC‐MS/MS: Biomarkers for tacrolimus nephrotoxicity after renal transplantation
JP2023169161A (ja) インスリン及びｃ－ペプチドの定量の方法
Tavares et al. 1, 5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics
WO2011140093A2 (fr) Détection et suivi d'une hépatite graisseuse non alcoolique
Kemperman et al. Comparative urine analysis by liquid chromatography− mass spectrometry and multivariate statistics: method development, evaluation, and application to proteinuria
Šoić et al. High-throughput human complement C3 N-glycoprofiling identifies markers of early onset type 1 diabetes mellitus in children
WO2012143514A1 (fr) Procédé de diagnostic d'une atteinte hépatique basé sur un profil métabolomique
EP3884280B1 (fr) Procédés et kits permettant de diagnostiquer un dysfonctionnement du foie chez un sujet
Macioszek et al. Comprehensive metabolic signature of renal dysplasia in children. A multiplatform metabolomics concept
AU2022227248A1 (en) Protein and metabolite blood biomarkers for the diagnosis of brugada syndrome
Forte et al. New approach for early and specific Alzheimer disease diagnosis from different plasma biomarkers
Jia et al. Plasma phospholipid metabolic profiling and biomarkers of mouse IgA nephropathy
WO2018007422A1 (fr) Identification des sous-types des maladies du foie stéatosiques d'origine non alcoolique (nafld) chez l'homme
CN113866285B (zh) 用于糖尿病诊断的生物标志物及其应用
EP4599253A1 (fr) Utilisation de profils d'isoformes d'albumine pour caractérisation d'étiologie et de gravité des lésions hépatiques
Tang et al. Serum biomarker of diabetic peripheral neuropathy indentified by differential proteomics
US11899027B2 (en) Diagnostic methods based on lipid profiles
Li et al. Diagnostic performance of sex-specific modified metabolite patterns in urine for screening of prediabetes
Kim et al. Comparative analysis of serum proteomes of patients with cardiovascular disease
Chen et al. A Multiplatform approach for the discovery of novel drug-induced kidney injury biomarkers
López Bascón Analytical strategies to improve qualitative and quantitative determination in metabolomics by mass spectrometry
CN114264767A (zh) 用于糖尿病诊断的生物标志物及其用途

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250403

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)